PhD Candidate in Functional Genomics and Pancreatic Cancer Research; part time 65% (m/w/d)

LMU Klinikum München; München; On-site; EUR 32,000 - 52,000; Part time

Benefits offered by this job

Further education and training

Job ticket

Company pension scheme

Discounts

Childcare services

Staff accommodation (if available)

Mobile work (if suitable)

Job summary

LMU Klinikum München invites applications for a part-time PhD Candidate position in Functional Genomics and Pancreatic Cancer Research at Campus Großhadern. The 65% appointment supports doctoral work within the DEFEAT-PDAC consortium, focusing on drug synergy mapping in pancreatic ductal adenocarcinoma.

Candidates should hold a Master’s in biology or related life science, with hands-on experience in molecular biology and interest in cancer research.

Qualifications

• Master’s degree or equivalent in biology/biochem/molecular medicine or life-science.

Responsibilities

• Work on the DEFEAT-PDAC project mapping drug synergy in pancreatic cancer.

Skills

Strong communication

Teamwork

Scientific curiosity

Independent work

English proficiency

Education

Master’s degree in Biology or related field

Tools

CRISPR technologies

Genetic screens

Proteomics

Next-generation sequencing

Bioinformatic analysis

Job description

PhD Candidate in Functional Genomics and Pancreatic Cancer Research; part time 65%

(m/f/d)

Workplace

Campus Großhadern

Working hours

Part time

Institution

Medizinische Klinik II (Gastroenterologie und Hepatologie)

Department

Doktorarbeit Forschungslabor

Date of entry

At the earliest possible date

Application deadline

01.10.2026

Reference Number

2026-K-0328

The Hospital of the University of Munich, Germany, is one of the largest and most competitive university hospitals in Germany and Europe. 48 specialized hospitals, departments and institutions harbouring excellent research and education provide patient care at the highest medical level with around 12.000 employees.

Scope of duties

• Work on the project “Global mapping of drug synergy landscapes using massively parallel Cas13d genetic interaction screening” within the German Cancer Aid-funded DEFEAT-PDAC consortium
• Investigate therapeutically relevant genetic dependencies and drug combinations in pancreatic ductal adenocarcinoma
• Perform and analyze high-throughput genetic interaction screens, particularly using Cas13d-based screening approaches
• Plan and conduct molecular and cell biological experiments to validate identified targets and drug synergies
• Investigate rational combination therapies, including combinations with RAS/KRAS inhibitors
• Work with pancreatic cancer cell lines and additional preclinical model systems
• Apply modern methods in cell biology, molecular biology, functional genomics and proteomics
• Quantitatively analyze, interpret and document experimental data
• Collaborate closely with research groups and technology platforms within the DEFEAT-PDAC network
• Present research findings at project meetings and scientific conferences and contribute to scientific publications

Our requirements

• A successfully completed university degree, preferably a Master’s degree or equivalent, in biology, biochemistry, molecular medicine, biotechnology or a related life-science discipline
• Strong interest in cancer biology, functional genomics, mechanisms of therapy resistance and translational cancer research
• Practical experience in cell and molecular biology, for example mammalian cell culture, transfection, RNA and protein analysis, immunoblotting or microscopy
• Previous experience with CRISPR-based technologies, genetic screens, proteomics, next-generation sequencing or bioinformatic data analysis is an advantage, but not mandatory
• Motivation to learn new experimental technologies and quantitative analysis methods
• A careful, structured and independent approach to scientific work
• Scientific curiosity, high motivation and enthusiasm for experimental research
• Strong communication and teamwork skills and an interest in working in an interdisciplinary and international research environment
• Very good written and spoken English
• German language skills are not required

Our offer

• An innovative and challenging PhD project within the DEFEAT-PDAC consortium, a national and internationally connected research network funded by German Cancer Aid
• An international and interdisciplinary research environment at the interface of cancer biology, functional genomics, proteomics and clinical translation
• State-of-the-art laboratories and access to advanced screening, proteomics, sequencing and data-analysis platforms
• Close collaboration with basic scientists, bioinformaticians and clinician scientists
• Structured scientific supervision and support for your professional and personal development
• Opportunities to participate in national and international conferences, workshops and training programmes
• A collaborative, supportive and inspiring working environment that encourages scientific independence and the development of your own ideas
• Employment according to the German public-sector collective agreement, including annual leave and additional benefits in accordance with the applicable regulations
• The position is initially funded for three years. Subject to a positive scientific re-evaluation, an extension for up to two additional years is possible
• The position is based at the LMU University Hospital, Campus Großhadern, in Munich
• The remuneration is based on the Collective Agreement for the Public Service of the Federal States (TV-Ärzte) including all allowances customary in the public service.

Offers and services of the employer

• Further education and training
• Job ticket
• Company pension scheme
• Discounts
• Childcare services
• Staff accommodation (if available)
• Mobile work (if suitable)

Mrs. PD Dr. Bange, Tanja

089 4400 76180

Disabled persons will be preferentially considered in case of equal qualification. Presentation costs cannot be refunded.

We ask you for your understanding that postal applications will not be returned, but will be destroyed in accordance with data protection regulations. The data usage information also applies to postal applications.